Our new website is coming soon, give it a try now and let us have your feedback. Take me to the Beta



Register
Login:
Share:
Email Facebook Twitter


TSX Lithium explorer International Lithium Corp prepares to drill at Raleigh Lake
Exclusive: Hardman & Co Investor Forum - Severn Trent, Calculus Capital, Volta Finance, Residential


Regulatory News


Grant of Options

Wed, 22nd May 2019 18:24


RNS Number : 9132Z
Amryt Pharma PLC
22 May 2019

22 May 2019

AIM: AMYT

Euronext Growth: AYP

Amryt Pharma plc

("Amryt" or the "Company")

Grant of Options and Notification of Transactions by Persons Discharging Managerial Responsibilities

Amryt announces that the Remuneration Committee has approved the grant of 3,407,734 share options ("Options") to subscribe for ordinary shares of 1p each in the Company ("Shares") under the Employee Share Option Plan 2016 (the "Plan") to Joe Wiley, CEO, and Rory Nealon, CFO, details of which are set out in the table below.

The Options have an exercise price of 12.64p ("Exercise Price"). These options may be exercised as follows:

?

25% of the total Options granted may be exercised 12 months after the date of grant;

?

a further 25% of the total Options granted may be exercised 24 months after the date of grant; and

?

the balance of the Options may be exercised 36 months after the date of grant.

All Options are subject to change of control provisions and expire on the seventh anniversary of their grant.

Following the grants of these options, the following Directors have the following options:

Director

Options granted

Total Options now held

Joe Wiley

1,896,239

3,957,369

Rory Nealon

1,511,495

2,335,947

PDMR Dealings

The notification of dealing forms for each Director can be found below. This announcement is made in accordance with Article 19 of the EU Market Abuse Regulation 596/2014.

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Joe Wiley

2.

Reason for the notification

a)

Position / status

Director

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Amryt Pharma plc

b)

Legal entity identifier

213800BOS8WAJO2BEQ38

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary shares of £0.01 each

Identification code

ISIN: GB00BDD1LS57

b)

Nature of the transaction

Grant of options under the Employee Share Option Plan 2016 with an exercise price of 12.64p to purchase 1,896,239 ordinary shares.

c)

Currency

British Pounds

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

1,896,239

e)

Aggregated information

· Aggregated volume

· Aggregated price

1,896,239

N/A

f)

Date of the transaction

21 May 2019

g)

Place of the transaction

Outside a trading venue

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Rory Nealon

2.

Reason for the notification

a)

Position / status

Director

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Amryt Pharma plc

b)

Legal entity identifier

213800BOS8WAJO2BEQ38

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary shares of £0.01 each

Identification code

ISIN: GB00BDD1LS57

b)

Nature of the transaction

Grant of options under the Employee Share Option Plan 2016 with an exercise price of 12.64p to purchase 1,511,495 ordinary shares.

c)

Currency

British Pounds

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

1,511,495

e)

Aggregated information

·Aggregated volume

·Aggregated price

1,511,495

N/A

f)

Date of the transaction

21 May 2019

g)

Place of the transaction

Outside a trading venue

Enquiries:

Amryt Pharma plc

+353 (1) 518 0200

Joe Wiley, CEO

Rory Nealon, CFO/COO

Shore Capital

+44 (0) 20 7408 4090

Financial Advisor, NOMAD and Joint Broker

Edward Mansfield, Mark Percy, Daniel Bush

Stifel

+44 (0) 20 7710 7600

Joint Broker

Jonathan Senior, Ben Maddison

Davy

+353 (1) 679 6363

Euronext Growth Advisor and Joint Broker

John Frain, Daragh O'Reilly

Consilium Strategic Communications

+44 (0) 20 3709 5700

Amber Fennell, Matthew Neal, David Daley

About Amryt

Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases.

Lojuxta® is an approved treatment for adult patients with the rare cholesterol disorder - Homozygous Familial Hypercholesterolaemia ("HoFH"). This disorder impairs the body's ability to remove low density lipoprotein ("LDL") cholesterol ("bad" cholesterol) from the blood, typically leading to abnormally high blood LDL cholesterol levels in the body from before birth - often ten times more than people without HoFH - and subsequent aggressive and premature narrowing and blocking of blood vessels. Lojuxta® is indicated as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without LDL apheresis in adult patients with HoFH.

Amryt is the marketing authorisation holder and has an exclusive licence to sell Lojuxta® (lomitapide) across the European Economic Area, Middle East and North Africa, Switzerland, Turkey, Israel, Russia, the Commonwealth of Independent States and the non-EU Balkan states.

Amryt's lead development candidate, AP101, is a potential treatment for Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no treatment. It is currently in Phase 3 clinical trials and recently reported positive unblinded interim efficacy analysis results and is anticipated will be fully enrolled by end of H2 2019. The European and US market opportunity for EB is estimated to be in excess of $1 billion.

In March 2018, Amryt in-licenced a pre-clinical gene-therapy platform technology, AP103, which offers a potential treatment for patients with Recessive Dystrophic Epidermolysis Bullosa, a subset of EB, and is also potentially relevant to other genetic disorders.

In May 2019, Amryt announced the planned acquisition of Aegerion Pharmaceuticals. This Transaction will put Amryt on the path to creating a rare and orphan disease company with a diversified offering of multiple commercial and development stage assets and will provide it with scale to support further growth. The Transaction will give Amryt an expanded commercial footprint to market two US and EU approved products, lomitapide (Juxtapid® (US/ROW) / Lojuxta® (EU)) and metreleptin (Myalept® (US) / Myalepta® (EU)). Amryt's leadership team already has a deep knowledge of both these products and since December 2016 has successfully commercialized Lojuxta® across Europe and the Middle East.

For more information on Amryt, please visit www.amrytpharma.com.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHSEAFWEFUSEFI


Related Shares:
(AMYT)



Back to Regulatory News


Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk


Home  |  Contact Us  |  About Us  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy  |  Mobile Site  |  About this website design


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.